Published in Acta Neuropathol on January 01, 2002
Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med (2011) 3.28
Caspase activation precedes and leads to tangles. Nature (2010) 3.24
The many faces of tau. Neuron (2011) 2.89
Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology. Brain (2010) 2.33
Case records of the Massachusetts General Hospital. Case 9-2015. A 31-year-old man with personality changes and progressive neurologic decline. N Engl J Med (2015) 1.97
Post-translational modification: nature's escape from genetic imprisonment and the basis for dynamic information encoding. Wiley Interdiscip Rev Syst Biol Med (2012) 1.81
Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. Sci Rep (2012) 1.77
Identification of oligomers at early stages of tau aggregation in Alzheimer's disease. FASEB J (2012) 1.70
Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am J Pathol (2006) 1.68
Drosophila models of neurodegenerative diseases. Annu Rev Pathol (2009) 1.67
Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice. Neurobiol Dis (2010) 1.60
Activation of GSK-3 and phosphorylation of CRMP2 in transgenic mice expressing APP intracellular domain. J Cell Biol (2005) 1.59
Mitochondrial oxidative stress causes hyperphosphorylation of tau. PLoS One (2007) 1.55
Tau loss attenuates neuronal network hyperexcitability in mouse and Drosophila genetic models of epilepsy. J Neurosci (2013) 1.54
MARK/PAR1 kinase is a regulator of microtubule-dependent transport in axons. J Cell Biol (2004) 1.49
Targeting phospho-Ser422 by active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic approach. Curr Alzheimer Res (2012) 1.41
Acetylated tau, a novel pathological signature in Alzheimer's disease and other tauopathies. Brain (2012) 1.38
Tau phosphorylation sites work in concert to promote neurotoxicity in vivo. Mol Biol Cell (2007) 1.37
Pin1 has opposite effects on wild-type and P301L tau stability and tauopathy. J Clin Invest (2008) 1.37
Amyloid-β oligomers induce synaptic damage via Tau-dependent microtubule severing by TTLL6 and spastin. EMBO J (2013) 1.31
PAR-1 kinase phosphorylates Dlg and regulates its postsynaptic targeting at the Drosophila neuromuscular junction. Neuron (2007) 1.31
Co-localization of amyloid beta and tau pathology in Alzheimer's disease synaptosomes. Am J Pathol (2008) 1.27
Magnetic resonance imaging improves cerebrospinal fluid biomarkers in the early detection of Alzheimer's disease. J Alzheimers Dis (2009) 1.26
Neurotransmitters drive combinatorial multistate postsynaptic density networks. Sci Signal (2009) 1.24
Silencing of CDK5 reduces neurofibrillary tangles in transgenic alzheimer's mice. J Neurosci (2010) 1.23
Dysregulation of insulin signaling, glucose transporters, O-GlcNAcylation, and phosphorylation of tau and neurofilaments in the brain: Implication for Alzheimer's disease. Am J Pathol (2009) 1.21
Spred1 and TESK1--two new interaction partners of the kinase MARKK/TAO1 that link the microtubule and actin cytoskeleton. Mol Biol Cell (2008) 1.19
GSK-3β, a pivotal kinase in Alzheimer disease. Front Mol Neurosci (2014) 1.18
ADF/Cofilin-actin rods in neurodegenerative diseases. Curr Alzheimer Res (2010) 1.18
iTRAQ analysis of complex proteome alterations in 3xTgAD Alzheimer's mice: understanding the interface between physiology and disease. PLoS One (2008) 1.16
Phosphorylation of tau at Thr212, Thr231, and Ser262 combined causes neurodegeneration. J Biol Chem (2010) 1.16
Increased CDK5 expression in HIV encephalitis contributes to neurodegeneration via tau phosphorylation and is reversed with Roscovitine. Am J Pathol (2011) 1.15
The dendritic hypothesis for Alzheimer's disease pathophysiology. Brain Res Bull (2013) 1.14
Stress hormone leads to memory deficits and altered tau phosphorylation in a model of Alzheimer's disease. J Alzheimers Dis (2012) 1.13
Tau-based treatment strategies in neurodegenerative diseases. Neurotherapeutics (2008) 1.13
PAK5 kinase is an inhibitor of MARK/Par-1, which leads to stable microtubules and dynamic actin. Mol Biol Cell (2005) 1.12
Soluble tau species, not neurofibrillary aggregates, disrupt neural system integration in a tau transgenic model. J Neuropathol Exp Neurol (2011) 1.10
A critical role for the PAR-1/MARK-tau axis in mediating the toxic effects of Aβ on synapses and dendritic spines. Hum Mol Genet (2011) 1.10
Dissociation of tau toxicity and phosphorylation: role of GSK-3beta, MARK and Cdk5 in a Drosophila model. Hum Mol Genet (2008) 1.09
Retracted Decrease in age-related tau hyperphosphorylation and cognitive improvement following vitamin D supplementation are associated with modulation of brain energy metabolism and redox state. Neuroscience (2014) 1.08
Frontal cortex neuropathology in dementia pugilistica. J Neurotrauma (2012) 1.08
The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease. Neurobiol Aging (2007) 1.07
Loss of nonphosphorylated neurofilament immunoreactivity in temporal cortical areas in Alzheimer's disease. Neuroscience (2009) 1.06
Model based dynamics analysis in live cell microtubule images. BMC Cell Biol (2007) 1.06
Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance. Hum Mol Genet (2013) 1.05
Activated actin-depolymerizing factor/cofilin sequesters phosphorylated microtubule-associated protein during the assembly of alzheimer-like neuritic cytoskeletal striations. J Neurosci (2009) 1.03
Are tau aggregates toxic or protective in tauopathies? Front Neurol (2013) 1.03
Amyloid beta-mediated cell death of cultured hippocampal neurons reveals extensive Tau fragmentation without increased full-length tau phosphorylation. J Biol Chem (2011) 1.03
Alzheimer's disease: insights from Drosophila melanogaster models. Trends Biochem Sci (2009) 1.03
Is abnormal axonal transport a cause, a contributing factor or a consequence of the neuronal pathology in Alzheimer's disease? Future Neurol (2009) 1.02
Tau Ser262 phosphorylation is critical for Abeta42-induced tau toxicity in a transgenic Drosophila model of Alzheimer's disease. Hum Mol Genet (2010) 1.01
Sensitive quantitative assays for tau and phospho-tau in transgenic mouse models. Neurobiol Aging (2012) 1.01
Rapid accumulation of endogenous tau oligomers in a rat model of traumatic brain injury: possible link between traumatic brain injury and sporadic tauopathies. J Biol Chem (2013) 1.01
Structure and regulation of MARK, a kinase involved in abnormal phosphorylation of Tau protein. BMC Neurosci (2008) 1.00
Alzheimer's disease and anesthesia. Front Neurosci (2011) 1.00
Loss of axonal mitochondria promotes tau-mediated neurodegeneration and Alzheimer's disease-related tau phosphorylation via PAR-1. PLoS Genet (2012) 0.99
DAPK activates MARK1/2 to regulate microtubule assembly, neuronal differentiation, and tau toxicity. Cell Death Differ (2011) 0.99
Staging of Alzheimer's pathology in triple transgenic mice: a light and electron microscopic analysis. Int J Alzheimers Dis (2010) 0.98
Tau potentiates nerve growth factor-induced mitogen-activated protein kinase signaling and neurite initiation without a requirement for microtubule binding. J Biol Chem (2010) 0.96
Microtubule affinity-regulating kinase 2 (MARK2) turns on phosphatase and tensin homolog (PTEN)-induced kinase 1 (PINK1) at Thr-313, a mutation site in Parkinson disease: effects on mitochondrial transport. J Biol Chem (2012) 0.95
High-content siRNA screening of the kinome identifies kinases involved in Alzheimer's disease-related tau hyperphosphorylation. BMC Genomics (2010) 0.95
Anesthetic isoflurane increases phosphorylated tau levels mediated by caspase activation and Aβ generation. PLoS One (2012) 0.95
β-carboline compounds, including harmine, inhibit DYRK1A and tau phosphorylation at multiple Alzheimer's disease-related sites. PLoS One (2011) 0.95
Mammalian target of rapamycin hyperactivity mediates the detrimental effects of a high sucrose diet on Alzheimer's disease pathology. Neurobiol Aging (2013) 0.94
LRRK2 phosphorylates novel tau epitopes and promotes tauopathy. Acta Neuropathol (2013) 0.94
Inhibition of Pin1 reduces glutamate-induced perikaryal accumulation of phosphorylated neurofilament-H in neurons. Mol Biol Cell (2007) 0.94
Causes versus effects: the increasing complexities of Alzheimer's disease pathogenesis. Expert Rev Neurother (2010) 0.93
Tau reduction prevents Aβ-induced axonal transport deficits by blocking activation of GSK3β. J Cell Biol (2015) 0.93
A DNA damage-activated checkpoint kinase phosphorylates tau and enhances tau-induced neurodegeneration. Hum Mol Genet (2010) 0.93
Molecular implication of PP2A and Pin1 in the Alzheimer's disease specific hyperphosphorylation of Tau. PLoS One (2011) 0.92
Tau pathology involves protein phosphatase 2A in parkinsonism-dementia of Guam. Proc Natl Acad Sci U S A (2014) 0.92
Implicating calpain in tau-mediated toxicity in vivo. PLoS One (2011) 0.91
Tau as a biomarker of neurodegenerative diseases. Biomark Med (2008) 0.91
An unbiased approach to identifying tau kinases that phosphorylate tau at sites associated with Alzheimer disease. J Biol Chem (2013) 0.90
Drosophila melanogaster as a model organism of brain diseases. Int J Mol Sci (2009) 0.90
Tau protein modifications and interactions: their role in function and dysfunction. Int J Mol Sci (2014) 0.89
Tau as a therapeutic target for Alzheimer's disease. Curr Alzheimer Res (2011) 0.89
Characteristics of tau oligomers. Front Neurol (2013) 0.89
Removing endogenous tau does not prevent tau propagation yet reduces its neurotoxicity. EMBO J (2015) 0.88
Phospho-dependent ubiquitination and degradation of PAR-1 regulates synaptic morphology and tau-mediated Aβ toxicity in Drosophila. Nat Commun (2012) 0.88
Extensive p-tau pathology and SDS-stable p-tau oligomers in Alzheimer's cortical synapses. Brain Pathol (2012) 0.88
Photobiomodulation with near infrared light mitigates Alzheimer's disease-related pathology in cerebral cortex - evidence from two transgenic mouse models. Alzheimers Res Ther (2014) 0.88
Pseudohyperphosphorylation causing AD-like changes in tau has significant effects on its polymerization. Biochemistry (2009) 0.87
Hyperphosphorylated tau is elevated in Alzheimer's disease with psychosis. J Alzheimers Dis (2014) 0.87
Acetylation: a new key to unlock tau's role in neurodegeneration. Alzheimers Res Ther (2014) 0.86
Chronic effects of mild neurotrauma: putting the cart before the horse? J Neuropathol Exp Neurol (2015) 0.86
Monte carlo simulations of tau proteins: effect of phosphorylation. Biophys J (2010) 0.86
Two-dimensional electrophoresis of tau mutants reveals specific phosphorylation pattern likely linked to early tau conformational changes. PLoS One (2009) 0.86
Roles of cholesterol and lipids in the etiopathogenesis of Alzheimer's disease. J Biomed Biotechnol (2006) 0.86
Cerebrospinal fluid levels of tau phosphorylated at threonine 181 in patients with Alzheimer's disease and vascular dementia. Neurol Sci (2008) 0.86
The formation of tau pore-like structures is prevalent and cell specific: possible implications for the disease phenotypes. Acta Neuropathol Commun (2014) 0.85
Characterization of Early Pathological Tau Conformations and Phosphorylation in Chronic Traumatic Encephalopathy. J Neuropathol Exp Neurol (2016) 0.85
Deregulation of protein phosphatase 2A and hyperphosphorylation of τ protein following onset of diabetes in NOD mice. Diabetes (2012) 0.85
Identification of changes in neuronal function as a consequence of aging and tauopathic neurodegeneration using a novel and sensitive magnetic resonance imaging approach. Neurobiol Aging (2017) 0.84
Passive immunotherapy of tauopathy targeting pSer413-tau: a pilot study in mice. Ann Clin Transl Neurol (2015) 0.84
Proteomic analysis of protein phosphorylation and ubiquitination in Alzheimer's disease. Methods Mol Biol (2009) 0.84
Inhibition of serine palmitoyltransferase reduces Aβ and tau hyperphosphorylation in a murine model: a safe therapeutic strategy for Alzheimer's disease. Neurobiol Aging (2013) 0.84
Tau aggregation and toxicity in tauopathic neurodegenerative diseases. J Alzheimers Dis (2008) 0.84
Dual modification of Alzheimer's disease PHF-tau protein by lysine methylation and ubiquitylation: a mass spectrometry approach. Acta Neuropathol (2011) 0.84
An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage (2006) 25.52
The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.26
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
Live tissue intrinsic emission microscopy using multiphoton-excited native fluorescence and second harmonic generation. Proc Natl Acad Sci U S A (2003) 8.92
Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron (2009) 7.02
Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease. Nature (2008) 6.89
Propagation of tau pathology in a model of early Alzheimer's disease. Neuron (2012) 6.23
National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol (2011) 6.00
Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science (2007) 5.49
The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb Cortex (2008) 5.36
Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J Neurosci (2005) 4.71
Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol (2002) 4.42
Family-based association between Alzheimer's disease and variants in UBQLN1. N Engl J Med (2005) 4.34
Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. Proc Natl Acad Sci U S A (2005) 4.34
ARAMEMNON, a novel database for Arabidopsis integral membrane proteins. Plant Physiol (2003) 4.15
Oligomeric amyloid beta associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques. Proc Natl Acad Sci U S A (2009) 3.86
Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol (2007) 3.83
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol (2014) 3.75
Human LilrB2 is a β-amyloid receptor and its murine homolog PirB regulates synaptic plasticity in an Alzheimer's model. Science (2013) 3.59
Abeta plaques lead to aberrant regulation of calcium homeostasis in vivo resulting in structural and functional disruption of neuronal networks. Neuron (2008) 3.46
Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. Neuron (2013) 3.43
Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med (2011) 3.28
Caspase activation precedes and leads to tangles. Nature (2010) 3.24
Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci (2002) 3.20
Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J Neuropathol Exp Neurol (2002) 3.12
Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimers Dement (2011) 3.05
Dysferlin interacts with annexins A1 and A2 and mediates sarcolemmal wound-healing. J Biol Chem (2003) 3.00
Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo. Nat Cell Biol (2006) 2.93
Clinical, pathological, and biochemical spectrum of Alzheimer disease associated with PS-1 mutations. Am J Geriatr Psychiatry (2004) 2.70
Tau fragmentation, aggregation and clearance: the dual role of lysosomal processing. Hum Mol Genet (2009) 2.69
Abeta oligomers cause localized Ca(2+) elevation, missorting of endogenous Tau into dendrites, Tau phosphorylation, and destruction of microtubules and spines. J Neurosci (2010) 2.66
Synchronous hyperactivity and intercellular calcium waves in astrocytes in Alzheimer mice. Science (2009) 2.65
Hsp70 Reduces alpha-Synuclein Aggregation and Toxicity. J Biol Chem (2004) 2.62
Neurotransmitter-triggered transfer of exosomes mediates oligodendrocyte-neuron communication. PLoS Biol (2013) 2.61
Transcription analysis of arabidopsis membrane transporters and hormone pathways during developmental and induced leaf senescence. Plant Physiol (2006) 2.57
Distinct roles in vivo for the ubiquitin-proteasome system and the autophagy-lysosomal pathway in the degradation of α-synuclein. J Neurosci (2011) 2.53
Amyotrophic lateral sclerosis-associated SOD1 mutant proteins bind and aggregate with Bcl-2 in spinal cord mitochondria. Neuron (2004) 2.53
Region-specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy. Am J Pathol (2006) 2.47
Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker Study. Neurology (2013) 2.47
Amyloid beta induces the morphological neurodegenerative triad of spine loss, dendritic simplification, and neuritic dystrophies through calcineurin activation. J Neurosci (2010) 2.46
Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. J Neurosci (2002) 2.44
gamma-Secretase heterogeneity in the Aph1 subunit: relevance for Alzheimer's disease. Science (2009) 2.43
Formation of toxic oligomeric alpha-synuclein species in living cells. PLoS One (2008) 2.35
Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology. Brain (2010) 2.33
Meta-analysis of Parkinson's disease: identification of a novel locus, RIT2. Ann Neurol (2012) 2.20
Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice. Proc Natl Acad Sci U S A (2003) 2.13
Structural magnetic resonance imaging in established and prodromal Alzheimer disease: a review. Alzheimer Dis Assoc Disord (2003) 2.12
Novel late-onset Alzheimer disease loci variants associate with brain gene expression. Neurology (2012) 2.08
The low density lipoprotein receptor-related protein (LRP) is a novel beta-secretase (BACE1) substrate. J Biol Chem (2005) 2.08
Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neurol (2003) 2.05
In vivo microdialysis reveals age-dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic mice. J Neurosci (2011) 2.00
Cortical synaptic integration in vivo is disrupted by amyloid-beta plaques. J Neurosci (2004) 1.99
Tau pathophysiology in neurodegeneration: a tangled issue. Trends Neurosci (2009) 1.99
Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. J Clin Invest (2005) 1.94
Single-molecule investigation of the interference between kinesin, tau and MAP2c. EMBO J (2002) 1.91
Nonsteroidal anti-inflammatory drugs lower Abeta42 and change presenilin 1 conformation. Nat Med (2004) 1.91
Heat-shock protein 70 modulates toxic extracellular α-synuclein oligomers and rescues trans-synaptic toxicity. FASEB J (2010) 1.90
Clinical prediction of Alzheimer disease dementia across the spectrum of mild cognitive impairment. Arch Gen Psychiatry (2007) 1.88
Apolipoprotein E4 effects in Alzheimer's disease are mediated by synaptotoxic oligomeric amyloid-β. Brain (2012) 1.87
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement (2011) 1.87
The co-chaperone carboxyl terminus of Hsp70-interacting protein (CHIP) mediates alpha-synuclein degradation decisions between proteasomal and lysosomal pathways. J Biol Chem (2005) 1.85
Demonstration by FRET of BACE interaction with the amyloid precursor protein at the cell surface and in early endosomes. J Cell Sci (2003) 1.85
Interaction of the cytosolic domains of sorLA/LR11 with the amyloid precursor protein (APP) and beta-secretase beta-site APP-cleaving enzyme. J Neurosci (2006) 1.83
Missorting of tau in neurons causes degeneration of synapses that can be rescued by the kinase MARK2/Par-1. J Neurosci (2007) 1.82
Uniform polarity microtubule assemblies imaged in native brain tissue by second-harmonic generation microscopy. Proc Natl Acad Sci U S A (2003) 1.81
Amyloid-beta antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. J Neurosci (2003) 1.81
A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg Med Chem Lett (2002) 1.79
Inducible expression of Tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs. J Biol Chem (2005) 1.79
The potential for beta-structure in the repeat domain of tau protein determines aggregation, synaptic decay, neuronal loss, and coassembly with endogenous Tau in inducible mouse models of tauopathy. J Neurosci (2008) 1.78
TorsinA and heat shock proteins act as molecular chaperones: suppression of alpha-synuclein aggregation. J Neurochem (2002) 1.77
In vivo imaging reveals dissociation between caspase activation and acute neuronal death in tangle-bearing neurons. J Neurosci (2008) 1.77
Protein kinase MARK/PAR-1 is required for neurite outgrowth and establishment of neuronal polarity. Mol Biol Cell (2002) 1.76
MARKK, a Ste20-like kinase, activates the polarity-inducing kinase MARK/PAR-1. EMBO J (2003) 1.75
Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseases. Proc Natl Acad Sci U S A (2006) 1.73
APOE epsilon 3/ epsilon 4 heterozygotes have an elevated proportion of apolipoprotein E4 in cerebrospinal fluid relative to plasma, independent of Alzheimer's disease diagnosis. Exp Neurol (2003) 1.73
Beta-secretase activity increases with aging in human, monkey, and mouse brain. Am J Pathol (2004) 1.70
Familial Alzheimer's disease presenilin 1 mutations cause alterations in the conformation of presenilin and interactions with amyloid precursor protein. J Neurosci (2005) 1.70
The tau of MARK: a polarized view of the cytoskeleton. Trends Biochem Sci (2009) 1.69
Impaired spine stability underlies plaque-related spine loss in an Alzheimer's disease mouse model. Am J Pathol (2007) 1.69
Interaction of reelin with amyloid precursor protein promotes neurite outgrowth. J Neurosci (2009) 1.68
Crystal structure of the complete integrin alphaVbeta3 ectodomain plus an alpha/beta transmembrane fragment. J Cell Biol (2009) 1.68
Efficient inhibition of the Alzheimer's disease beta-secretase by membrane targeting. Science (2008) 1.67
Endocytic receptor LRP together with tPA and PAI-1 coordinates Mac-1-dependent macrophage migration. EMBO J (2006) 1.66
Inhibition of the NFAT pathway alleviates amyloid β neurotoxicity in a mouse model of Alzheimer's disease. J Neurosci (2012) 1.64
Molecular dissection of the interaction between amyloid precursor protein and its neuronal trafficking receptor SorLA/LR11. Biochemistry (2006) 1.63
Converse modulation of toxic alpha-synuclein oligomers in living cells by N'-benzylidene-benzohydrazide derivates and ferric iron. Biochem Biophys Res Commun (2009) 1.63
Anthraquinones inhibit tau aggregation and dissolve Alzheimer's paired helical filaments in vitro and in cells. J Biol Chem (2004) 1.62
In vivo optical imaging of amyloid aggregates in brain: design of fluorescent markers. Angew Chem Int Ed Engl (2005) 1.60
Dopamine D1 activation potentiates striatal NMDA receptors by tyrosine phosphorylation-dependent subunit trafficking. J Neurosci (2006) 1.59
Arabidopsis STN7 kinase provides a link between short- and long-term photosynthetic acclimation. Plant Cell (2009) 1.58
Tau-induced defects in synaptic plasticity, learning, and memory are reversible in transgenic mice after switching off the toxic Tau mutant. J Neurosci (2011) 1.57
The apoE isoform binding properties of the VLDL receptor reveal marked differences from LRP and the LDL receptor. J Lipid Res (2005) 1.57
Age-dependent cerebrovascular dysfunction in a transgenic mouse model of cerebral amyloid angiopathy. Brain (2007) 1.55
Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra. J Neurochem (2007) 1.55
Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am J Pathol (2002) 1.54
BACE is degraded via the lysosomal pathway. J Biol Chem (2005) 1.53
Examination of the clinicopathologic continuum of Alzheimer disease in the autopsy cohort of the National Alzheimer Coordinating Center. J Neuropathol Exp Neurol (2013) 1.52
Mechanisms of protein seeding in neurodegenerative diseases. JAMA Neurol (2013) 1.51